Assessment of PD-L1 levels in tumor tissue is currently recommended for a better selection of candidates for first-line treatment with the anti-PD-L1 agents atezolizumab or pembrolizumab in patients with locally advanced urothelial cancer, mBC or no candidates/refractory to cisplatin-based chemotherapy. Here, CD274 is linked to neoplasm.